Aurobindo Pharma Limited has scheduled its 39th Annual General Meeting (AGM) for Thursday, August 27, 2026, at 3:30 p.m. IST. The meeting will be conducted exclusively through Video Conferencing (VC) or Other Audio Visual Means (OAVM), requiring shareholders to participate remotely rather than in person. This virtual format ensures accessibility for investors while adhering to the company's governance protocols for shareholder engagement.

The Notice of the 39th AGM and the Integrated Annual Report for the financial year 2025-26 will be dispatched electronically to all shareholders who have registered their email addresses with the Company or Depositories. For shareholders without registered email IDs, a physical letter containing the weblink and access path will be sent to enable them to view the documents. These materials will also be publicly available on the Company’s website under the disclosures section.

Key Dates and Procedures

Shareholders must note the specific dates regarding share transfers and voting eligibility. Pursuant to Section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and Share Transfer Books will remain closed during the following period:

This closure period is inclusive of both days and is strictly enforced to determine the list of members entitled to vote at the AGM. No transfer of shares will be processed during this window.

Regulatory Compliance

The intimation was issued by B. Adi Reddy, Company Secretary, and digitally signed on July 29, 2026. The notification was submitted to both the National Stock Exchange of India Limited (NSE) and the Bombay Stock Exchange (BSE), referencing Company Code No. AUROPHARMA for NSE and Company Code No. 524804 for BSE. This filing ensures transparency and compliance with statutory requirements for public limited companies listed in India.

What the Numbers Show

While this announcement pertains to corporate governance rather than financial performance, the timing of the AGM coincides with the conclusion of the financial year 2025-26. Shareholders should monitor the release of the Integrated Annual Report, which will provide detailed insights into the company’s operational and financial results for FY26. The remote nature of the meeting underscores the continued reliance on digital infrastructure for shareholder communication in the pharmaceutical sector.

Aurobindo Pharma Limited will host an analyst and investor call on August 6, 2026, at 8:30 AM IST to discuss its unaudited financial results for the first quarter ended June 30, 2026. The event provides stakeholders with an opportunity to review the company’s performance in Q1FY27 and address queries regarding operational and financial outcomes. This disclosure ensures timely access to material information for investors and market participants following the release of quarterly earnings.

The announcement was made pursuant to Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the schedule to the Listing Department of the National Stock Exchange of India Limited and the Corporate Relations Department of BSE Limited. B. Adi Reddy, Company Secretary, digitally signed the communication on July 29, 2026.

Call Details

Participants can join the earnings call through Zoom by pre-registering via the provided link or accessing the session directly through the browser. The earnings presentation will be available on the company’s website after the results announcement.

Regulatory Compliance

The notice was issued to ensure compliance with listing obligations under SEBI regulations. The company code for Aurobindo Pharma Limited is AUROPHARMA on NSE and 524804 on BSE. The corporate office is located in Hyderabad Knowledge City, Ranga Reddy District, Telangana, while the registered office is situated in Ameerpet, Hyderabad.

What This Means for Investors

The earnings call serves as a critical channel for management to contextualize the Q1FY27 financial data. Investors should note that the discussion will focus on unaudited figures, which may be subject to revision upon final audit. The availability of the presentation post-call allows for detailed analysis of segment performance and key metrics disclosed during the quarter.